The Effect of Atorvastatin Administration before Percutaneous Coronary Intervention on Stable Coronary Artery Disease Against Event of Periprocedural Myocardial Infarction

Abstract

Abstract Statin administration before Percutaneous Coronary Intervention procedures (PCI) is proved in reducing the incidence of Myocardial Peri-Procedural (PMI) infarction. This research was to compare between of pre-treatment 40mg Atorvastatin administered two hours before PCI in Stable Coronary Artery Disease (SCAD) patient and without pre-treatment in reducing the rate of periprocedural myocardial infarction. This study was a Clinical Trial with pretest-posttest control group open-label randomized design. Data were analyzed using Kolmogorov Smirnov Sample test and Chi Square Test. The PMI incidence in the atorvastatin group was 0% and in the control group was 8.3% (p = 0.489). The maximum CK-MB value after PCI in the atorvastatin group was 6.4ng/ml and 25.49ng/ml in the control group. Administration of 40mg Atorvastatin in SCAD patients before undergoing PCI shows a tendency of a decrease in PMI incidence.